Peptides DB
Research-centric peptide and protocol reference hub
Study 5 of 12Cyclic Glycine-Proline (cGP) literatureHuman vaccines & immunotherapeutics · Review2026

Comparative innate immune responses across major RNA and DNA viral infections: Mechanisms, immunopathology, and therapeutic perspectives.

Innate immune responses differ significantly between RNA and DNA viruses, influencing infection severity and therapeutic strategies.

Read at Human vaccines & immunotherapeuticsAdd to compare

Where it sits

this study against the rest of the cyclic glycine-proline (cgp) corpus
8
Preclinical
3
Observational
0
Open-label
0
Randomised
1
Reviews · this one

Summary and findings

This review examines innate immune responses to major RNA and DNA viral infections, focusing on mechanisms and therapeutic perspectives. It highlights differences in interferon dynamics and immune evasion between RNA and DNA viruses. Therapeutic strategies targeting innate immunity are discussed.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
2026

Abstract

The authors’ words, as Human vaccines & immunotherapeutics supplied them

Innate immunity is the first defense against viral infections, limiting viral replication and initiating adaptive immunity. Viral pathogens are recognized by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), (RIG-I-like receptors) RLRs, and the (cyclic GMP-AMP synthase) cGAS-STING pathway, which trigger interferon production and antiviral responses. This review compares innate immune responses to major RNA viruses (influenza, SARS-CoV-2, HIV) and DNA viruses (HSV, HBV, CMV). While these viruses activate similar pathways, they differ in interferon dynamics, inflammatory responses, immune cell activation, and immune evasion mechanisms. RNA viruses often induce rapid and strong innate responses, whereas many DNA viruses establish persistence through immune modulation. Dysregulated innate immunity can contribute to cytokine storms, chronic inflammation, and tissue damage. Therapeutic strategies targeting innate immunity, such as interferons, cytokine inhibitors, PRR agonists, and host-directed antivirals, may improve outcomes. Infection severity depends on the timing, magnitude, and regulation of innate immune responses.

Background

The study addresses how innate immune responses vary across different viral infections, which is crucial for understanding viral pathogenesis and developing therapeutic strategies. Innate immunity is the first line of defense against viruses, and its dysregulation can lead to severe outcomes. Understanding these mechanisms is important for improving treatment approaches.

Methods

This is a review article that compares innate immune responses to major RNA and DNA viruses. It discusses mechanisms such as interferon production, immune cell activation, and immune evasion. The review synthesizes existing literature without presenting new experimental data.

Results

The review highlights that RNA viruses typically induce rapid and strong innate immune responses, while DNA viruses often establish persistence through immune modulation. It discusses how dysregulated innate immunity can contribute to severe outcomes like cytokine storms. Therapeutic strategies targeting these pathways are explored.

Interpretation

The findings align with existing literature on the differences between RNA and DNA virus interactions with the innate immune system. While the review provides a comprehensive overview, the lack of new data limits its clinical applicability. The therapeutic strategies discussed are promising but require further validation in clinical trials.

Key findings

  • RNA viruses like influenza and SARS-CoV-2 induce rapid and strong innate responses.
  • DNA viruses such as HSV and HBV often establish persistence through immune modulation.
  • Dysregulated innate immunity can lead to cytokine storms and chronic inflammation.
  • Therapeutic strategies include interferons, cytokine inhibitors, and PRR agonists.

Limitations

  • No new experimental data
  • Relies on existing literature
  • Lacks specific quantitative findings
  • No direct clinical trial data discussed

Elsewhere in the Cyclic Glycine-Proline (cGP) corpus

CScreening of Stereochemically Defined 2,5-Diketopiperazines Identifies Autophagy Inducers without mTORC1 Suppressionbiorxiv-preprint · 2026 · Not reported in abstract.In vitroCDevelopment of a novel electrochemical impedance spectroscopy-based biosensor for bone formation-resorption biomarker determination in body fluids.Bioelectrochemistry (Amsterdam, Netherlands) · 2026 · β-CTX detection range: 10-60 pg mL^-1, LOD: 2.9 pg mL^-1In vitroCReduced mediators released by cyanobacteria during exoelectrogenesis detected using differential pulse voltammetry.Bioelectrochemistry (Amsterdam, Netherlands) · 2026 · Multiple light-enhanced oxidation peaks at 0.1-0.65 V vs. SCE.In vitroCRational design of a sulfonium-stabilized cyclic temporin-SHf as a potential food preservative.Food microbiology · 2026 · Ten-fold increase in antimicrobial potency relative to native peptide.In vitroCGlycodeoxycholic and deoxycholic bile acids impair recognition and spatial memory in adult mice, and reduce central CREB-BDNF signaling and cytokine expression with neuroanatomical specificity.Gut microbes · 2026 · GDCA impaired recognition memory after 10 days.AnimalCDiscovery of a novel STING-binding peptide associated with reduced cGAMP-induced inflammatory gene expression.Journal of enzyme inhibition and medicinal chemistry · 2026 · Peptide-1 Kd = 0.15 ± 0.01 μMIn vitro